AXL, a well-characterized tumor promotion receptor tyrosine kinases with high levels of expression and activation in many types of tumors and sarcoma, including an aggressive subtype of liposarcoma, was also evaluated in a study by May, Caitlin D et al. The results indicated that AXL is responsible for DDLPS and PLS's aggression, so AXL may be a promising candidate in treating this kind of rare but destructive cancer (76). This evidence concerns the gene NTRK1 and liposarcoma.